Essential Thrombocythemia with JAK2 Mutation: Standard Treatments, Natural Strategies, and the Risks of Self-Medication
Essential Thrombocythemia (ET) is a type of myeloproliferative neoplasm (MPN) that leads to chronically elevated platelet counts. In patients with a JAK2 mutation , the risk of blood clots or bleeding increases significantly, especially in those considered high-risk (typically age 60 or older or with a history of thrombosis). Treatment is aimed at lowering platelet counts and reducing these risks, most commonly through cytoreductive therapy , such as hydroxyurea (HU) , and the use of hydroxyurea (HU) . While medical therapies remain the standard of care, some patients explore natural or dietary strategies to support platelet control and reduce clotting risk—particularly when traditional medications cause intolerable side effects. However, self-medicating without medical supervision carries important risks and should be approached with caution and full transparency with your healthcare provider. A Personal Approach to Platelet Management Some patients report managing their ET symp...